Seqens Seqens

X
[{"orgOrder":0,"company":"Grand River Aseptic Manufacturing","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GRAM Partners with Johnson & Johnson on Manufacturing in Fight Against COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Grand River Aseptic Manufacturing","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Grand River Aseptic Manufacturing to Fill and Finish Smallpox\/Monkeypox Vaccines and Accelerate Domestic Supply","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Grand River Aseptic Manufacturing

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            JYNNEOS is a suspension for subcutaneous injection (0.5 mL) based on a live, attenuated vaccinia virus (Modified Vaccinia Ankara, MVA-BN), incapable of replicating in the body, yet still capable of eliciting a potent immune response.

            Lead Product(s): Live Nonreplicating Smallpox And Monkeypox Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Jynneos

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Bavarian Nordic

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 19, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The agreement includes the technical transfer and fill and finish manufacture of Johnson & Johnson's SARS-CoV-2 vaccine candidate.

            Lead Product(s): Ad26.COV2-S

            Therapeutic Area: Infections and Infectious Diseases Product Name: JNJ-78436735

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Johnson & Johnson

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership September 25, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY